8.91
0.32 (3.73%)
| Penutupan Terdahulu | 8.59 |
| Buka | 8.04 |
| Jumlah Dagangan | 40,763 |
| Purata Dagangan (3B) | 125,265 |
| Modal Pasaran | 34,713,324 |
| Harga / Jualan (P/S) | 91.86 |
| Harga / Buku (P/B) | 4.43 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Aug 2025 - 18 Aug 2025 |
| EPS Cair (TTM) | -13.22 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 28.27% |
| Nisbah Semasa (MRQ) | 0.960 |
| Aliran Tunai Operasi (OCF TTM) | -9.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.67 M |
| Pulangan Atas Aset (ROA TTM) | -71.24% |
| Pulangan Atas Ekuiti (ROE TTM) | -268.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Quantum Biopharma Ltd. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.38 |
|
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 11.41% |
| % Dimiliki oleh Institusi | 23.49% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Cetera Trust Company, N.A | 30 Jun 2025 | 250 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |